Telephone: +1-631-444-9538; Fax: +1-631-444-9553;
Cancer Stem Cells
Version of Record online: 20 SEP 2012
Copyright © 2012 AlphaMed Press
Volume 30, Issue 10, pages 2065–2075, October 2012
How to Cite
Zhu, C., Cheng, K.-W., Ouyang, N., Huang, L., Sun, Y., Constantinides, P. and Rigas, B. (2012), Phosphosulindac (OXT-328) Selectively Targets Breast Cancer Stem Cells In Vitro and in Human Breast Cancer Xenografts. STEM CELLS, 30: 2065–2075. doi: 10.1002/stem.1139
Author contributions: C.Z.: collection and/or assembly of data, data analysis and interpretation, manuscript writing, and final approval of manuscript; K.W.C., N.O., L.H., and Y.S.: design, collection and/or assembly of data, data analysis and interpretation, manuscript writing, and final approval of manuscript; P.C.C.: provision of study material and final approval of manuscript; B.R.: conception and design, financial support, provision of study material, data analysis and interpretation, manuscript writing, and final approval of manuscript.
Disclosure of potential conflicts of interest is found at the end of this article.
First published online in STEM CELLSEXPRESS May 31, 2012.
- Issue online: 20 SEP 2012
- Version of Record online: 20 SEP 2012
- Accepted manuscript online: 31 MAY 2012 10:34AM EST
- Manuscript Accepted: 9 MAY 2012
- Manuscript Received: 14 DEC 2011
- National Institutes of Health National Cancer Institute. Grant Number: R01CA139454
- Department of Defense. Grant Number: W81XWH1010873
Additional Supporting Information may be found in the online version of this article.
|SC_11-1195_sm_supplFigure1.tif||1643K||Fig. S1. CD24/CD44 expression in breast CSCs and non-CSCs.|
|SC_11-1195_sm_supplFigure2.tif||1720K||Fig. S2 (A) HMLERshTRL and HMLERshECAD cells were mixed at a ratio about 1:1 and plated in 6- well plates. After incubation with DMSO or PS (30 μM) for 7 days as in Methods, cells were stained for CD24/CD44 and analyzed by flow cytometry. (B) HMLERshTRL and HMLERshECAD cells were treated with DMSO or PS (15 or 30 μM) for 7 days, and labeled with BrdU for 30 min. BrdU incorporation and PI staining were then analyzed by flow cytometry. (C) Cell proliferation was determined by using CellTiter-Blue assay after PS treatment.|
|SC_11-1195_sm_supplFigure3.tif||339K||Fig. S3. (A) Expression levels of E-cadherin and vimentin were determined by immunoblot after TGFβ1 induced EMT. (B) Expression levels of E-cadherin and vimentin in HMLER cells treated with TGFβ1 and /or PS.|
|SC_11-1195_sm_supplFigure4.pdf||947K||Fig. S4. (A) Nuclear β-catenin levels in HMLERTGFβ1 cells treated with PS determined by immunoblotting. Loading control: histone H3. (B) Immunofluorescence images of HMLERshTRL and HMLERshECAD cells treated as shown for 24 h. Upper row: staining with PI visualizes the nuclei. Middle row: Staining with an anti-β-catenin mAb. (C) HMLERTGFβ1 cells were transfected with indicated siRNA (20 nM). At 60 h after transfection, cells were stained for CD24/CD44 and analyzed by flow cytometry. (D & E)The inhibition of PS on β-catenin signaling pathway was determined by immunoblot and immunofluorescence in MDA-MB-321 cells.|
|SC_11-1195_sm_supplFigure5.tif||214K||Fig. S5. Real-time PCR result of snail expression in HMLER cells.|
|SC_11-1195_sm_supplFigure6.pdf||814K||Fig. S6. Expression/localization of β-catenin, vimentin and ALDH1 were detected by immunofluorescence in MDA-MB-231 xenografts.|
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.